Update on the development of the NT-proBNP assay

11 Feb 2026 08:23 CET

Moss, 11 February 2026

Gentian Diagnostics ASA announces an update on the development of its NT proBNP
assay. Recent investigations have confirmed that the current assay version does
not demonstrate sufficiently robust performance in the lower concentration
ranges, particularly around clinically important cut off levels.

Based on these findings, Gentian has identified several measures that may
enhance assay performance; however, these require a redesign of the test. The
company has therefore initiated activities to investigate whether redesigning
the assay could improve robustness, with initial results to be shared once
available.

At the present stage, Gentian is not able to provide a reliable updated timeline
for the release of the Research Use Only (RUO) product nor for the subsequent
commercial launch of the NT proBNP assay. The company expects to present revised
development timelines during Q2 2026. Consequently, the planned NT proBNP
webcast will also be postponed.

Commenting on the development, Gentian CEO Matti Heinonen said:
“This is certainly a disappointing development and a setback for the project. As
the assay did not meet the performance requirements needed to pass the
verification stage, we have decided to return the project to the optimisation
phase. This approach carries a higher level of development risk, but it is
necessary as we now evaluate whether a redesigned assay can deliver a viable and
commercially relevant NT proBNP product.”

For further information, please contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525

About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in
vitro diagnostic reagents. Our mission is to innovate diagnostic efficiency for
better treatment decisions. Gentian’s expertise and focus lie within
immunoassays, specifically for infections, inflammation, kidney disease and
heart failure. By converting existing and clinically relevant biomarkers to the
most efficient, high-throughput analysers, the company contributes to saving
costs and protecting life. Gentian Diagnostics is headquartered in Moss, Norway,
serving the global human and veterinary diagnostics markets through sales and
representative offices in Sweden, USA, and China. For more information, please
visit www.gentian.com.

More information:
Access the news on Oslo Bors NewsWeb site